SCHEMBL2129121

SCHEMBL2129121

CC(C)(C)c1cc(-c2ccccc2)ncn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ASIC3 Q9UHC3 2/20 0.53
MIF P14174 1/20 0.53
KMO O15229 3/20 0.49
KMT2A Q03164 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HRH4 Q9H3N8 1/20 0.45
MEN1 O00255 1/20 0.44
TSHR P16473 1/20 0.44
RECQL P46063 1/20 0.44
FAAH O00519 1/20 0.41
KDM4E B2RXH2 2/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28332495 0.98 ASIC3 (0.52) ASIC3MIFKMOKMT2ANPC1
SCHEMBL28222550 0.98 ASIC3 (0.52) ASIC3MIFKMOKMT2ANPC1
SCHEMBL27932758 0.98 ASIC3 (0.52) ASIC3MIFKMOKMT2ANPC1
SCHEMBL29550010 0.98 ASIC3 (0.52) ASIC3MIFKMOKMT2ANPC1
SCHEMBL16477266 0.84 KMT2A (0.51) ASIC3MIFKMOKMT2ANPC1
SCHEMBL21125938 0.83 MIF (0.38) ASIC3MIFKMOKMT2ANPC1
SCHEMBL10220555 0.83 ABL1 (0.44) ASIC3MIFNPC1RAB9ASMN1; SMN2
SCHEMBL10336516 0.82 ASIC3 (0.55) ASIC3MIFKMOKMT2ANPC1
SCHEMBL10220591 0.81 KMO (0.50) MIFKMONPC1RAB9ASMN1; SMN2
SCHEMBL22059823 0.81 MIF (0.34) ASIC3MIFKMOKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577456-B2 Light-emitting element, light-emitting device, electronic device, lighting device, and novel organic compound SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2026-03-17 US disclosed
CN-113880884-B Light-emitting element, light-emitting device, electronic apparatus, and lighting device 株式会社半导体能源研究所 2025-06-03 CN disclosed
US-20250160211-A1 Light-Emitting Element, Light-Emitting Device, Electronic Appliance, And Lighting Device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2025-05-15 US disclosed
US-20250126962-A1 Light-Emitting Element SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2025-04-17 US disclosed
US-20250120248-A1 Light-Emitting Element, Light-Emitting Device, Display Device, Electronic Device, and Lighting Device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2025-04-10 US disclosed
US-20250089443-A1 Light-Emitting Element, Light-Emitting Device, Display Device, Electronic Device, and Lighting Device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2025-03-13 US disclosed
US-12250884-B2 Light-emitting element, light-emitting device, electronic appliance, and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2025-03-11 US disclosed
US-12239010-B2 Light-emitting element, light-emitting device, electronic device, and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2025-02-25 US disclosed
US-20250063937-A1 Light-Emitting Element SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2025-02-20 US disclosed
US-12161007-B2 Light-emitting element, light-emitting device, display device, electronic device, and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2024-12-03 US disclosed
US-7863291-B2 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands BRISTOL-MYERS SQUIBB COMPANY (US) 2011-01-04 US disclosed
US-7741281-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-22 US disclosed
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2010-04-22 US disclosed
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2010-04-22 US disclosed
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY 2009-10-29 US disclosed
US-20080182862-A1 N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2008-07-31 US disclosed
US-20080107623-A1 Inhibitors of Hepatitis C Virus BRISTOL-MYERS SQUIBB COMPANY 2008-05-08 US disclosed
US-20080107624-A1 Inhibitors of Hepatitis C Virus BRISTOL-MYERS SQUIBB COMPANY 2008-05-08 US disclosed
US-20080107625-A1 Inhibitors of Hepatitis C Virus BRISTOL-MYERS SQUIBB COMPANY 2008-05-08 US disclosed
US-20070099825-A1 ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients BRISTOL-MYERS SQUIBB COMPANY 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA5, CHRNA6 ASIC3 1435/4885MIF 4879/4885KMO 932/4885
US-20080107623-A1 Inhibitors of Hepatitis C Virus HAVCR2, HCCS, VIP ASIC3 4246/4885MIF 1364/4885KMO 4746/4885
US-20070099825-A1 ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients TERT, VIP, YWHAZ ASIC3 4725/4885MIF 2742/4885KMO 3261/4885
US-20080107624-A1 Inhibitors of Hepatitis C Virus HAVCR2, MRPS23, HCCS ASIC3 3671/4885MIF 1877/4885KMO 4652/4885
US-20250063937-A1 Light-Emitting Element HPRT1, APRT, LAGE3 ASIC3 280/4885MIF 2202/4885KMO 4151/4885
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA5, CHRNA6 ASIC3 1435/4885MIF 4879/4885KMO 932/4885
US-20080182862-A1 N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS AXL, TYRO3, ERBB3 ASIC3 2770/4885MIF 2822/4885KMO 1744/4885
US-12239010-B2 Light-emitting element, light-emitting device, electronic device, and lighting device LAGE3, L1CAM, LOXL2 ASIC3 2497/4885MIF 1199/4885KMO 180/4885
US-12577456-B2 Light-emitting element, light-emitting device, electronic device, lighting device, and novel organic compound SUN2, LEF1, CTNND1 ASIC3 1118/4885MIF 1521/4885KMO 294/4885
US-20080107625-A1 Inhibitors of Hepatitis C Virus HAVCR2, HCCS, VIP ASIC3 4246/4885MIF 1364/4885KMO 4746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.